Atara Biotherapeutics (LSE:0HIY) - Stock Price, News & Analysis

0HIY Stock Overview

Engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. More details

0HIY fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	1/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Trading at 81.8% below our estimate of its fair value

Revenue is forecast to grow 9.7% per year

Earnings have grown 8.1% per year over the past 5 years

Trading at good value compared to peers and industry

Risk Analysis

Negative shareholders equity

Highly volatile share price over the past 3 months compared to the UK market

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap ($60M)

+ 2 more risks

Atara Biotherapeutics, Inc. Competitors

Tissue Regenix Group

AIM:TRX

UK£41.0m

Arecor Therapeutics

AIM:AREC

UK£28.9m

Bioventix

AIM:BVXP

UK£193.6m

Avacta Group

AIM:AVCT

UK£170.1m

Price History & Performance

Summary of all time highs, changes and price drops for Atara Biotherapeutics
Historical stock prices
Current Share Price	US$10.42
52 Week High	US$39.40
52 Week Low	US$6.56
Beta	0.49
11 Month Change	22.56%
3 Month Change	39.27%
1 Year Change	-36.86%
33 Year Change	-97.58%
5 Year Change	n/a
Change since IPO	-98.88%

Recent updates

Shareholder Returns

	0HIY	GB Biotechs	GB Market
7D	-13.4%	-5.2%	0.8%
1Y	-36.9%	-20.1%	6.6%

Return vs Industry: 0HIY underperformed the UK Biotechs industry which returned -20.1% over the past year.

Return vs Market: 0HIY underperformed the UK Market which returned 6.6% over the past year.

Price Volatility

Is 0HIY's price volatile compared to industry and market?
0HIY volatility
0HIY Average Weekly Movement	17.4%
Biotechs Industry Average Movement	9.6%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0HIY's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0HIY's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

Founded	Employees	CEO	Website
2012	159	Cokey Nguyen	www.atarabio.com

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis.

Atara Biotherapeutics, Inc. Fundamentals Summary

How do Atara Biotherapeutics's earnings and revenue compare to its market cap?
0HIY fundamental statistics
Market cap	US$60.20m
Earnings (TTM)	-US$133.16m
Revenue (TTM)	US$100.44m

0.6x

P/S Ratio

-0.5x

P/E Ratio

Is 0HIY overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0HIY income statement (TTM)
Revenue	US$100.44m
Cost of Revenue	US$180.37m
Gross Profit	-US$79.93m
Other Expenses	US$53.23m
Earnings	-US$133.16m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-23.47
Gross Margin	-79.58%
Net Profit Margin	-132.58%
Debt/Equity Ratio	0%

How did 0HIY perform over the long term?

See historical performance and comparison

0HIY Stock Overview

Rewards

Risk Analysis

Atara Biotherapeutics, Inc. Competitors

AIM:TRX

UK£41.0m

AIM:AREC

UK£28.9m

AIM:BVXP

UK£193.6m

AIM:AVCT

UK£170.1m

Price History & Performance

Recent News & Updates

New minor risk - Profitability

Third quarter 2024 earnings released: US$2.94 loss per share (vs US$16.40 loss in 3Q 2023)

New major risk - Revenue and earnings growth

Atara Biotherapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Atara Biotherapeutics, Inc. Appoints Eric Hyllengren as Chief Operating Officer

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $36 million.

Recent updates

New minor risk - Profitability

Third quarter 2024 earnings released: US$2.94 loss per share (vs US$16.40 loss in 3Q 2023)

New major risk - Revenue and earnings growth

Atara Biotherapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Atara Biotherapeutics, Inc. Appoints Eric Hyllengren as Chief Operating Officer

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $36 million.

Insufficient new directors

Second quarter 2024 earnings released: US$3.10 loss per share (vs US$16.92 loss in 2Q 2023)

Atara Biotherapeutics, Inc. Announces CEO Changes, Effective September 9, 2024

Atara Biotherapeutics Announces U.S. Fda Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-Cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

New major risk - Financial position

New minor risk - Insider selling

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA

First quarter 2024 earnings released: US$0.23 loss per share (vs US$0.72 loss in 1Q 2023)

Atara Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2024

Full year 2023 earnings released: US$2.61 loss per share (vs US$2.24 loss in FY 2022)

Atara Biotherapeutics, Inc. Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel®? Data in The Lancet Oncology

Atara Biotherapeutics, Inc. has announced a Derivatives Offering in the amount of $15 million.

Atara Biotherapeutics, Inc. Announces Termination of Manher (Aj) Joshi as Executive Vice President, Chief Medical Officer, Effective as of February 2, 2024

Atara Biotherapeutics, Inc. Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

Independent Director recently bought US$101k worth of stock

New minor risk - Market cap size

Atara Biotherapeutics, Inc. Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Financial position

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings released: US$0.66 loss per share (vs US$0.82 loss in 3Q 2022)

New major risk - Negative shareholders equity

Atara Biotherapeutics, Inc. Announces Plans to Submit Tab-cel® BLA in Second Quarter 2024 Following FDA Agreement on Comparability

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.68 loss per share (vs US$0.18 profit in 2Q 2022)

Atara Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Financial position

Atara Biotherapeutics, Inc. Announces Resignation of Beth Seidenberg from the Board of Directors

Insufficient new directors

President recently sold US$61k worth of stock

Atara Biotherapeutics, Inc. Announces Executive Changes

Full year 2022 earnings released: US$2.24 loss per share (vs US$3.63 loss in FY 2021)

Pierre Fabre and Atara Biotherapeutics Announce the Transfer of the European Commission Marketing Authorization for EBVALLO(TM)

Atara Biotherapeutics, Inc. to Report Q4, 2022 Results on Feb 08, 2023

Atara Biotherapeutics Announces Changes to Its Board of Directors

Atara Biotherapeutics, Inc. Appoints Carol Gallagher as Chair of the Board of Directors

Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (Allele) of Tab-Cel(R) At the 64Th American Society of Hematology (Ash) Annual Meeting

Atara Biotherapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Atara Biotherapeutics, Inc. Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022

CHMP Recommends Approval of Atara Biotherapeutics, Inc. Ebvallo (Tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics, Inc. to Terminate Kristin Yarema as Senior Vice President and Chief Commercial Officer, Effective as of November 15, 2022

Atara Biotherapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Now 35% undervalued

Atara Biotherapeutics, Inc. Announces Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS

Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-cel EMA Regulatory Progress

Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer

Atara and MSK Expects to Provide A Phase 1 Data Update for Ata2271 in Second Half 2022

Atara Biotherapeutics, Inc. Names Charlene Banard as Chief Technical Officer

Atara Biotherapeutics, Inc. Provides Update on ATA2271 Autologous CAR T Trial

Atara Biotherapeutics, Inc. to Report Fiscal Year 2021 Results on Feb 28, 2022

FUJIFILM Diosynth Biotechnologies California, Inc. entered into an asset purchase agreement to acquire T-Cell Operations and Manufacturing Facility in Thousand Oaks, California from Atara Biotherapeutics, Inc. (NasdaqGS:ATRA) for $100 million.

Atara Biotherapeutics, Inc. Lauds the Second High Impact Study This Month Solidifying EBV as the Primary Driver of the Development of MS